Arcutis Biotherapeutics (ARQT) Income towards Parent Company (2019 - 2026)

Arcutis Biotherapeutics' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$11.3 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 54.93% year-over-year to -$11.3 million; the TTM figure through Mar 2026 stood at -$2.4 million (up 98.15% YoY), while the FY2025 annual figure was -$16.2 million, up 88.45% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$11.3 million, down from $17.4 million in the prior quarter.
• The five-year high for Income towards Parent Company was $17.4 million in Q4 2025, with the low at -$107.7 million in Q3 2022.
• The 5-year median for Income towards Parent Company is -$44.8 million (2023), against an average of -$43.7 million.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company plunged 88.76% in 2022, then soared 260.98% in 2025.
• Arcutis Biotherapeutics' Income towards Parent Company stood at -$72.0 million in 2022, then rose by 7.96% to -$66.3 million in 2023, then surged by 83.72% to -$10.8 million in 2024, then jumped by 260.98% to $17.4 million in 2025, then slumped by 165.04% to -$11.3 million in 2026.
• Business Quant data shows ARQT's Income towards Parent Company at -$11.3 million in Q1 2026, $17.4 million in Q4 2025, and $7.4 million in Q3 2025.